Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $2.7 million
Deal Type : Licensing Agreement
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
Details : MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.
Product Name : Wynzora
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $2.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Endo Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada
Details : The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.
Product Name : Wynzora
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 15, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Endo Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : MC2-32
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MC2 Therapeutics Gets Positive FDA Feedback And Updates Expansion Strategy
Details : MC2-32 (previously RGRN-305) is a small molecule, HSP90 inhibitor. It is being evaluated in the phase II clinical trial studies for the treatment of hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : MC2-32
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25 VLS
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 23, 2023
Lead Product(s) : MC2-25 VLS
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25 CKD
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC2-25, a first-in-class di-peptide drug candidate functioning as an effective isocyanate scavenger, is presently undergoing Phase II clinical trial evaluation for the treatment of Chronic Kidney Disease-associated Pruritus.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : MC2-25 CKD
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : EPI Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...
Product Name : Wynzora
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : EPI Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP
Details : MC2-25 Cream is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracting the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2022
Lead Product(s) : MC2-25
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MC2-25 CKD-aP is formulated to be highly tolerable, moisturizing, convenient to use and it quickly absorbs into the skin allowing patients to get on with their life and their daily routines.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 09, 2022
Lead Product(s) : MC2-25
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable